Navigation Links
OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Date:3/25/2013

-based immunotherapy and NeoPulse therapy, to treat solid tumors. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform, to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers, using these powerful and targeted anti-cancer agents, has demonstrated selective destruction of cancerous cells – while sparing healthy normal tissues – during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse, targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected n
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... 2014 Apnea Sciences ( www.apneasciences.com ) announced ... Aliso Viejo , California.  Jimmy Fallon ... growth and worldwide expansion, a new facility with expanded ... anti snore cure have exceeded our expectations and thus ... now in 23 countries and will be increasing to ...
(Date:12/22/2014)... Dec. 22, 2014   TRU-D SmartUVC LLC, ... disinfection robot, announced today that the General Services Administration ... November 2019.   This newly formed agreement ... levels of government purchasers, including Department of Veteran Affairs ... Homeland Security contacts purchasing solutions for the Ebola effort ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
... 23, 2011 Isis Pharmaceuticals, Inc. (NASDAQ: ... infringement lawsuit against Santaris Pharma A/S and Santaris Pharma ... the Southern District of California.  Isis, infringement suit against ... and antisense drug discovery services to several pharmaceutical companies. ...
... Sept. 23, 2011 Amgen (NASDAQ: AMGN ... Vectibix® (panitumumab) studies will be presented at the 2011 ... in Stockholm, Sweden.   "The data being ... Amgen,s ongoing commitment to advancing the understanding of cancer ...
Cached Medicine Technology:Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma 2Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma 3Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 2Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 3Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 4Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 5Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 6Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 7Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 8Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 9Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress 10
(Date:12/24/2014)... 2014 The report “Stivarga (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... a drug which is used in the treatment of ... and is also prescribed to patients who suffer from ... approved is a multi-kinase inhibitor and it blocks many ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay News) ... one year will be allowed to donate blood in the United ... ban on donations from men who have sex with men. ... release a new draft guidance in early 2015 that would ultimately ... FDA is changing its policy based on data from other countries ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- A new, ... Food and Drug Administration. The agency on Tuesday ... for those who are overweight and have at least ... type 2 diabetes or high cholesterol. Patients taking ... a low-calorie diet and exercise regularly, the FDA noted. ...
(Date:12/24/2014)... Tara Haelle HealthDay Reporter ... are more likely to start smoking or drinking with ... (ADHD) or conduct disorder, new research suggests. ... the risk of substance use as [these] children approach ... at Cincinnati Pediatric Research Group, which is part of ...
(Date:12/24/2014)... Gluten, a protein found predominately in wheat ... intolerance to gluten, causing side effects that can range ... pain and fatigue. For this reason, Diet Doc created ... safe and fast weight loss while teaching patients how ... reaction. These gluten free diet plans combine the healthiest ...
Breaking Medicine News(10 mins):Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
... ... orthodontist, Dr. Inna Gellerman, kicks off holiday season with food drives, toy drives and ... ... , Dr. Inna Gellerman, celebrates the holiday season by participating in various community events, ...
... ... Medtronic founder, joins Dr. Jean Watson to launch The Million Nurse Global ... www.millionnurseproject.org ! . Nurses are uniting to celebrate the 2010 ... and two proposed United Nations Resolutions, together to radiate heart-centered Love and ...
... , ... With over 45 million uninsured in the ... Obama’s plans for health insurance reform in the United States, one ... transcends traditional boundaries. MediBid connects physicians to patients in a free-market ...
... ... has announced that they have added a new line of Natural ... Vitamins are produced on FDA registered and inspected facility operating since ... Medicine’s Nutritional vitamins and supplements make them safe, top quality products. ...
... ... company and "Top 100" Rochester, NY Growth Company, is partnering with AstraZeneca ... for the improved management of hypertension. The partnership program positions community ... a select group of Canadian retail pharmacy participants. , ...
... , AUBURN HILLS, Mich., Dec. ... integrated logistics services and highly customized supply chain solutions ... Worldwide Holdings, Inc. The terms of the transaction are ... , Addison, IL-based NAL is a third-party logistics (3PL) ...
Cached Medicine News:Health News:Long Island Children's Orthodontist, Dr. Inna Gellerman, Celebrates Season of Giving with Holiday Drives and Events 2Health News:The Million Nurse Global Caring Field Project Launches Jan. 1st, 2010 at Noon 2Health News:MediBid.com Empowers Physicians to Expand Their Fee for Service Practice with New Online Portal 2Health News:MediBid.com Empowers Physicians to Expand Their Fee for Service Practice with New Online Portal 3Health News:All Alternative Medicine Products LLC. Presents a New Line of Natural Nutritional Supplements and Vitamins 2Health News:All Alternative Medicine Products LLC. Presents a New Line of Natural Nutritional Supplements and Vitamins 3Health News:All Alternative Medicine Products LLC. Presents a New Line of Natural Nutritional Supplements and Vitamins 4Health News:PharmaSmart International, Inc and AstraZeneca Canada Enter Into Strategic Partnership to Elevate Pharmacy Based Hypertension Management 2Health News:syncreon Acquires NAL Worldwide Holdings Inc. 2Health News:syncreon Acquires NAL Worldwide Holdings Inc. 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: